(Press-News.org) WASHINGTON (March 30, 2014) — A medication traditionally used to treat gout is also effective at treating recurrent pericarditis, an inflammation of the sac-like covering around the heart, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In the first multicenter, double-blind trial to look at the use of colchicine for multiple recurrences of pericarditis, 240 patients were randomly assigned to either the study drug or placebo to examine the primary endpoint of recurrent pericarditis. The rate of disease recurrence was nearly twice as high in the placebo group as in the colchicine group (42.5 percent compared to 21.6 percent).
In addition, colchicine reduced patients' symptoms at 72 hours from 44.2 percent with the placebo to 19.2 percent in the colchicine group. It also reduced the number of recurrences per patient from 0.63 with placebo to 0.28 and reduced the hospitalization rate from 10 percent in the placebo group to 1.7 percent in the colchicine group. The drug also significantly improved patients' remission rates, with 59.2 percent in remission at one week in the placebo compared to 83.3 percent in the colchicine group.
"Based on this study, health care providers should feel confident with the use of colchicine as a first line drug in patients with multiple recurrences of pericarditis," said Massimo Imazio, M.D., cardiologist, Maria Vittoria Hospital, Torino, Italy, and lead investigator of the study. "Our study shows this is a safe and effective treatment solution for these patients."
Recurrent pericarditis is a syndrome in which inflammation of the sac around the heart recurs, even after the original cause is treated. Although the reason is often unknown, possible causes include infections, diseases such as cancer or kidney failure, and heart surgery or trauma.
Patients assigned to the colchicine group took 0.5 mg once (if they weighed 154 pounds or less) or twice (if more than 154 pounds) daily for six months, in addition to conventional anti-inflammatory therapy with aspirin, ibuprofen or indomethacin.
While colchicine is currently approved only for use with gout and Familial Mediterranean Fever (a genetic inflammatory disease), previous studies have also looked at the off-label use of colchicine added to conventional therapy in treating acute pericarditis. No clinical trials had examined the use of colchicine for multiple recurrences of pericarditis.
"A recurrence [of pericarditis] is often perceived by either the physician or the patient as a failure of previous treatments and a need for new therapies," Imazio said. "Other therapies, such as immunosuppressive options, are often more expensive and have more complications and side effects. We now know that colchicine can be added to the traditional treatment regimen [of anti-inflammatories and corticosteroids] and provide more cost-effective and easy-to-manage treatment with fewer side effects."
Gastrointestinal upset was the major limiting side effect in the colchicine group, reported in less than eight percent of patients. No serious adverse effects were recorded.
Imazio recommends additional research to better understand the causes of recurrent pericarditis and the optimal duration of treatment with colchicine.
INFORMATION:
Support for the study came from the Italian National Health Service, and study drugs were provided through an unrestricted grant from Acarpia, Madeira, Portugal.
The study will be published simultaneously in The Lancet medical journal online.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting.
The American College of Cardiology is a nonprofit medical society comprised of 47,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit CardioSource.org.
Anti-gout medication colchicine helps patients with recurrent pericarditis
Study finds drug linked to lower rates of disease reoccurrence and hospitalization
2014-03-31
ELSE PRESS RELEASES FROM THIS DATE:
Renal denervation patient registry finds low rate of adverse events
2014-03-31
WASHINGTON (March 30, 2014) — Patients with uncontrolled high blood pressure treated with renal denervation had low rates of adverse events and significant lowering of blood pressure at six months, according to a registry-based study presented at the American College of Cardiology's 63rd Annual Scientific Session.
The Global SYMPLICITY Registry is the first and largest dataset of patients with uncontrolled hypertension treated with renal denervation. The open-label, multicenter study was established to examine the safety and effectiveness of the procedure. Outcomes presented ...
Post-approval study of transcatheter pulmonary valve completes 1 year
2014-03-31
WASHINGTON (March 30, 2014) — The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in a small sample of patients with certain congenital heart defects, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
This multi-center study of 100 patients consecutively implanted with the Melody transcatheter pulmonary valve between July 2010 and July 2012 assessed the effectiveness of the device at six and 12 months based on the percentage ...
Cardiac resynchronization improves survival in heart failure patients
2014-03-31
WASHINGTON (March 30, 2014) — Patients in mild heart failure who receive a specialized pacemaker known as cardiac resynchronization therapy with a defibrillator (CRT-D) may live longer than those implanted with a traditional implantable cardioverter defibrillator (ICD), according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In the first study to look at CRT-D in mildly symptomatic patients, researchers found that patients with left bundle branch block implanted with a CRT-D had a 41 percent reduced risk of death compared ...
Blood test helps predict heart attack risk for patients with chest pain
2014-03-31
WASHINGTON (March 30, 2014) — Patients presenting to the emergency department with an undetectable level of the blood biomarker high-sensitivity cardiac troponin T, and whose ECGs show no sign of restricted blood flow, have a minimal risk of heart attack within 30 days, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In a study of all patients (14,636 in total) reporting to a Swedish emergency department with chest pain over a two-year period from 2010 to 2012, researchers examined patients' blood levels of high-sensitivity ...
The Atlantic Ocean dances with the sun and volcanoes
2014-03-31
Imagine a ballroom in which two dancers apparently keep in time to their own individual rhythm. The two partners suddenly find themselves moving to the same rhythm and, after a closer look, it is clear to see which one is leading.
It was an image like this that researchers at Aarhus University were able to see when they compared studies of solar energy release and volcanic activity during the last 450 years, with reconstructions of ocean temperature fluctuations during the same period.
The results actually showed that during the last approximately 250 years – since ...
Researchers reveal a new pathway through the sodium pump
2014-03-31
A study in The Journal of General Physiology provides new evidence that the ubiquitous sodium pump is more complex—and more versatile—than we thought.
The sodium pump is present in the surface membrane of all animal cells, using energy derived from ATP to transport sodium and potassium ions in opposite directions across the cell boundary. By setting up transmembrane gradients of these two ions, the pump plays a vital role in many important processes, including nerve impulses, heartbeats, and muscular contraction.
Now, Rockefeller University researchers Natascia Vedovato ...
Data show benefit of comprehensive lipid testing in determining risk for coronary heart disease
2014-03-31
Washington, D.C., March 31, 2014 ― Data presented from two meta-analyses using the Atherotech Vertical Auto Profile (VAP®) Lipid Panel showed the impact high-density lipoprotein (HDL) cholesterol and remnant lipoprotein (RLP) cholesterol have on determining a patient's risk for hard coronary heart disease (CHD) endpoints, such as myocardial infarction or coronary death. Each analysis examined men and women without prevalent CHD enrolled in both the Framingham Offspring and Jackson Heart studies over eight years. In both studies, HDL, the "good" cholesterol in the ...
Giving steroids during bypass surgery shows no benefit, some harm
2014-03-31
WASHINGTON (March 31, 2014) — Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. The finding, which stems from the largest randomized trial in cardiac surgery ever conducted, challenges a practice that many surgeons have used for decades.
"Based on these results, we suggest that steroids should not be used prophylactically during cardiac ...
Metformin fails to reduce heart failure after heart attack
2014-03-31
Washington (March 31, 2014) — The use of metformin, a common regulator of blood glucose for diabetics, does not help protect against heart failure in non-diabetic patients who have suffered a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
The GIPS-III trial is the first double-blind, randomized, placebo-controlled study conducted to evaluate whether four months of metformin treatment preserved left ventricular function in non-diabetic patients with acute myocardial infarction.
Metformin is commonly ...
Bariatric surgery beats medical therapy alone for managing diabetes
2014-03-31
WASHINGTON (March 31, 2014) — Gastric bypass and sleeve gastrectomy – two of the most commonly used bariatric surgeries – are more effective than intensive medical therapy alone when it comes to managing uncontrolled type 2 diabetes in overweight or obese patients after three years, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
STAMPEDE is the largest randomized controlled trial with one of the longest follow-ups to compare the effect of these two procedures to intensive medical therapy in helping patients achieve ...
LAST 30 PRESS RELEASES:
Community partners key to success of vaccine clinic focused on neurodevelopmental conditions
Low-carbon collaborative dual-layer optimization for energy station considering joint electricity and heat demand response
McMaster University researchers uncover potential treatment for rare genetic disorders
The return of protectionism: The impact of the Sino-US trade war
UTokyo and NARO develop new vertical seed distribution trait for soybean breeding
Research into UK’s use of plastic packaging finds households ‘wishcycle’ rather than recycle – risking vast contamination
Vaccine shows promise against aggressive breast cancer
Adverse events affect over 1 in 3 surgery patients, US study finds
Outsourcing adult social care has contributed to England’s care crisis, argue experts
The Lancet: Over 800 million adults living with diabetes, more than half not receiving treatment, global study suggests
New therapeutic approach for severe COVID-19: faster recovery and reduction in mortality
Plugged wells and reduced injection lower induced earthquake rates in Oklahoma
Yin selected as a 2024 American Society of Agronomy Fellow
Long Covid could cost the economy billions every year
Bluetooth technology unlocks urban animal secrets
This nifty AI tool helps neurosurgeons find sneaky cancer cells
Treatment advances, predictive biomarkers stand to improve bladder cancer care
NYC's ride-hailing fee failed to ease Manhattan traffic, new NYU Tandon study reveals
Meteorite contains evidence of liquid water on Mars 742 million years ago
Self-reported screening helped reduce distressing symptoms for pediatric patients with cancer
Which risk factors are linked to having a severe stroke?
Opening borders for workers: Abe’s profound influence on Japan’s immigration regime
How skills from hospitality and tourism can propel careers beyond the industry
Research shows managers of firms handling recalls should review media scrutiny before deciding whether to lobby
New model system for the development of potential active substances used in condensate modifying drugs
How to reduce social media stress by leaning in instead of logging off
Pioneering research shows sea life will struggle to survive future global warming
In 10 seconds, an AI model detects cancerous brain tumor often missed during surgery
Burden of RSV–associated hospitalizations in US adults, October 2016 to September 2023
Repurposing semaglutide and liraglutide for alcohol use disorder
[Press-News.org] Anti-gout medication colchicine helps patients with recurrent pericarditisStudy finds drug linked to lower rates of disease reoccurrence and hospitalization